Skip to main content
Allison Gatlin on Muck Rack

Allison Gatlin

Verified
California
As seen in: Investor's Business Daily, MIT Technology Review, MSN, USA Today, Yahoo News, Yahoo News New Zealand, Yahoo Finance, Chicago Tribune, Flipboard, Nasdaq, NewsBreak, Daily Press (Newport News, VA) and
Biopharma and medtech reporter for Investor's Business Daily, @IBDinvestors. @Cronkite_ASU alumna, taco connoisseur and twin mom. She/her.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Allison

Contact Allison, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.

|
By Allison Gatlin Verified
| Investor's Business Daily Verified
New HIV infections exceed 1.3 million worldwide every year, including north of 36,000 in the U.S. (© Chris Gash)
Open in Who Shared Issue with article?

Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies.

|
By Allison Gatlin Verified
| Investor's Business Daily Verified
Personalis (PSNL) stock popped Friday on a rumor Merck (MRK) and at least two other suitors are trying to buy the small genomics company. Needham analyst Mike Matson says Tempus AI (TEM) is likely one of the other bidders. Merck, a Dow Jones Industrial Average component, and Tempus AI both own stakes in Personalis. Other large diagnostic companies could also… Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
Open in Who Shared Issue with article?

Robotic Surgery Giant Crashes After Guiding To Its Slowest Growth In Years

|
By Allison Gatlin Verified
| Investor's Business Daily Verified
Intuitive Surgical (ISRG) stock plummeted late Thursday after the robotic surgery giant reported adjusted earnings of $2.80 per share on $2.89 billion in second-quarter sales. On average, analysts polled by FactSet expected Intuitive to earn $2.51 a share while reporting $2.83 billion in sales. During the year-earlier period, Intuitive Surgical had $2.19 earnings per share and $2.44 billion in sales.… Copyright ©2026 Investor's Business Daily, LLC. All rights reserved.
Open in Who Shared Issue with article?
See all 6,501 licensed articles (6,527 Total)